- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.06. | Merck antibody drug for RSV approved by FDA | ||
| 09.06. | Concentra to acquire Elevation Oncology in bid to eliminate another biotech 'zombie' | ||
| 09.06. | NewAmsterdam says cholesterol drug may also combat Alzheimer's | ||
| 09.06. | Metsera shares climb on early data for amylin-targeting obesity shot | ||
| 09.06. | Omada goes public in second recent digital health IPO | ||
| 09.06. | Merck claims study success with PCSK9 cholesterol pill | ||
| 09.06. | [Podcast] Trial Trailblazers: Behind clinical breakthroughs | ||
| 09.06. | The risk plan you forgot about: 3 considerations for your recruitment and enrollment strategy | ||
| 09.06. | The golden era of GLP-1 drugs: How will it impact medicine and society? | ||
| 06.06. | FDA meeting gives window into gene therapy field's angst | ||
| 06.06. | Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update | ||
| 05.06. | Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal | ||
| 04.06. | FDA to use new review tool on Sarepta's gene therapy work | ||
| 04.06. | Daiichi Sankyo struck gold with 'ADC' cancer drugs. Its new CEO has to figure out what's next. | ||
| 04.06. | Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO | ||
| 04.06. | Biotech funding plummets as Trump policies unnerve investors: Jefferies | ||
| 04.06. | Lilly partners with Camurus in search of a long-lasting obesity drug | ||
| 04.06. | Regeneron makes obesity push; Atai, Alto ink brain drug deals | ||
| 03.06. | Bayer drug could ease side effects of common breast cancer treatment, detailed data show | ||
| 03.06. | J&J data support earlier use of combo pill in prostate cancer | ||
| 03.06. | Kymera, with new data, takes early step toward a Dupixent-like pill | ||
| 02.06. | Bispecific competition, debating oral SERDs and a bold GLP-1 prediction | ||
| 02.06. | Sanofi to acquire Blueprint Medicines for up to $9.5B | ||
| 02.06. | Vera drug scores in closely watched study in rare kidney disease | ||
| 02.06. | Enhertu potential broadens as new data point to frontline breast cancer role |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .